ClinicalTrials.gg
CompletedNCT00044720Updated Aug 18, 2009

Study Evaluating Sirolimus in End Stage Renal Disease in High Risk Kidney Transplant Recipients

A Phase 4 interventional study of Rapamune in Chronic Kidney Failure, Graft vs Host Disease and Kidney Transplantation, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2009-08-18.

Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 4 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
484
Allocation
Randomized
Ages
13 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 12 studies testing sirolimus in Kidney Failure, Chronic — none open to participants now, none under way, none of them phase 3. Sirolimus · Kidney Failure, Chronic.

Enrollment
Largest of 12
484 · median 80
Phase 4
2 of 12
none open now
Registered
4th of 12
by date
Lead sponsor
1 of 12
Wyeth is now a wholly owned subsidiary of Pfizer

Among the 12 studies testing sirolimus in Kidney Failure, Chronic, this one has the largest enrollment, is one of 2 in phase 4, and was the 4th registered.

Kidney Failure, Chronic

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

None of the 12 studies testing sirolimus in Kidney Failure, Chronic is open now. The open studies under Kidney Failure, Chronic, anywhere →

About sirolimus

Sirolimus: first FDA approval 1999 (RAPAMUNE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 13 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing sirolimus in Kidney Failure, Chronic as a file.
02

Study summary

The incidence of efficacy failure at 12 months between two regimens.

03

Conditions studied

  • Chronic Kidney Failure
  • Graft vs Host Disease
  • Kidney Transplantation

Keywords

  • Kidney Transplant
04

Who can participate

Ages eligible
13 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 13 years or older, 40 kgs or more
  • End-stage renal disease
  • African-American/Black transplant recipient and/or repeat renal transplant recipient who lost a previous allograft

Exclusion criteria

Exclusion Criteria

  • Evidence of active infection
  • Evidence abnormal chest x-ray
  • Patients with .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Allocation
Randomized
Masking
None (open label)
Enrollment
484 participants (actual)

Interventions

06

Study locations

No study locations are listed for this record.

07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 18, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00044720
First posted
Sep 6, 2002
Primary completion
Jul 2005
Completion
Jul 2005
Last update
Aug 18, 2009

Study contacts

Medical Monitor, MD
study director · Wyeth is now a wholly owned subsidiary of Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sirolimus

Start the discussion